Peijia Medical Reports First Profit and Highlights TAVR Growth in 2026 Interim Results

Peijia Medical's Impressive Interim Results for 2026

On August 21, 2026, Peijia Medical, listed as 9996.HK, proudly announced its interim results for the first half of the year, marking a significant milestone in its financial journey. The report showcased the company's rapid growth in the transcatheter valve therapeutics and neurovascular intervention markets, highlighting the performance metrics that have contributed to its first-ever profit before tax.

A Strong Performance Amidst Growth

The six months ending June 30, 2026, illustrated remarkable financial growth for Peijia Medical, with total revenues reaching RMB424.5 million, a robust increase of 20.1% from the same period in 2025. The gross profit rose to RMB290.0 million, reflecting a 17.1% increase. Notably, the company's earnings before interest, taxes, depreciation, and amortization (EBITDA) recorded a positive RMB47.4 million, and it registered a profit before tax of RMB0.7 million, marking a significant turnaround from previous losses.

In addition, the net loss significantly decreased, showcasing an impressive 87.4% reduction to approximately RMB9.0 million. Cash generation also improved dramatically, with net cash from operating activities soaring to RMB49.4 million, an increase of 1,394.5% year-over-year. This swift rise in operational cash flow demonstrates Peijia's commitment to improving both profitability and operational efficiency.

TAVR Market Growth Driven by TaurusTrio®

A substantial contributor to Peijia's overall success has been its expansion in the transcatheter aortic valve replacement (TAVR) market. Revenue derived from TAVR grew to RMB207.3 million, up 28.3% from the previous year, bolstered by approximately 2,830 TAVR implantations, representing a 36.5% increase year-over-year.

The remarkable uptake of the TaurusTrio® transcatheter aortic valve system, launched after receiving approval from the National Medical Products Administration (NMPA) in December 2025, played a pivotal role. With a unique design catering to aortic regurgitation, the product met an essential need in the marketplace, offering a solution for patients previously facing limited options.

During this reporting period, TaurusTrio® sales exceeded 660 cases. The growing distribution network across provinces in China laid a solid foundation for continued market entry, underscoring the scalable nature of Peijia's commercial operations.

Strength in Neurointerventional Business

Alongside TAVR, Peijia's neurointerventional segment also demonstrated commendable growth, with revenues of RMB217.2 million, up 13.3% over the previous year's results. A substantial increase of 79% in segment profits reached RMB73.2 million, which reflects an ongoing improvement in profitability.

Peijia has been fortifying its neurointerventional portfolio by integrating proprietary innovations with strategic partnerships. Self-developed devices are gaining traction clinically, while key products such as the YonFlow® Flow Diverting Stent continue to scale commercially. Additionally, the collaboration with B. Braun Medical for exclusive distribution of the SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter in mainland China signifies an important step toward expanding its offerings pending regulatory approval.

Operational Excellence and Cost Management

Peijia Medical has committed itself to enhancing operational efficiencies while optimizing expense structures. The resilience of its gross profit margin of approximately 68.3% is a testament to effective governance amid rising competition and market challenges.

While the gross profit margin faced pressure due to pricing adjustments and rising initial manufacturing costs, Peijia managed to mitigate these challenges through product mix optimization and lean cost management strategies. Selling and distribution expenses decreased by 19.4%, evidencing sound financial management practices even as revenues increased.

The Path Ahead: Innovation and Expansion

Looking forward, the company remains resolute in advancing its innovation pipeline and expanding its global presence. With several products entering the review stage in China, as well as developments overseas, Peijia is laying the groundwork for sustainable growth.

Dr. Yi Zhang, Chairman and CEO, expressed optimism about the company's trajectory, emphasizing the importance of innovation and patient-centric values in their journey. His insights reflect a commitment to delivering high-quality medical solutions that not only drive financial performance but also improve patient outcomes significantly.

As Peijia Medical continues to scale its operations and launch transformative products, the coming months will undoubtedly be crucial in solidifying its position as a leader in the specialized medical device domain.